Vicore Pharma Holding AB (VICO) AI Stock Analysis

• Market Cap: kr2.01B
• Dividend Yield: N/A
• Average Volume (3M): 264.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: 63.85%
• Country: SE
• Employees: 33
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 234,579,120
• 10 Day Avg. Volume: 265,614
• 30 Day Avg. Volume: 264,708
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

Vicore Pharma Holding AB's stock is evaluated at a moderate level, reflecting its strong liquidity and financial resilience amidst continued net losses typical for biotech R&D phases. The technical analysis indicates potential short-term stability, while valuation remains tricky due to the negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Vicore Pharma Holding AB Business Overview & Revenue Model

Company Description

Vicore Pharma Holding AB (VICO) is a Sweden-based pharmaceutical company focused on the development of innovative therapies for rare lung diseases and related indications. The company's core products are centered around its proprietary angiotensin II type 2 receptor (AT2R) agonist platform, which aims to address unmet medical needs in pulmonary and fibrotic diseases. Vicore Pharma's lead product candidate, VP01 (C21), is being developed for conditions such as idiopathic pulmonary fibrosis (IPF) and COVID-19-induced acute respiratory distress syndrome (ARDS).

How the Company Makes Money

Vicore Pharma Holding AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's revenue model is largely dependent on the successful progression of its drug candidates through clinical trials, leading to potential licensing agreements, partnerships, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies. Vicore Pharma may also seek funding through grants and public or private investments to support its research and development activities.

Vicore Pharma Holding AB Financial Statement Overview

Summary

Vicore Pharma Holding AB demonstrates financial resilience with strong cash positions and no debt, but faces profitability challenges common in early-stage biotech firms. The negative cash flow from operations and reliance on equity financing highlights the company's focus on R&D without immediate revenue returns.

Income Statement

Vicore Pharma Holding AB has shown significant challenges in profitability. The net profit margin remains negative due to high operating losses, despite a revenue increase in 2024. The gross profit margin is positive but primarily due to the revenue recognition without associated costs. The company exhibits a history of net losses, which is typical for early-stage biotech firms focusing on R&D.

Balance Sheet

The balance sheet is relatively strong with no debt and substantial cash reserves, indicating good liquidity. The equity ratio is high, which is positive for financial stability. However, the continuous accumulation of losses affects the return on equity, which remains negative. The company maintains a strong equity position, providing a buffer against operational risks.

Cash Flow

Cash flow from operations is consistently negative, reflecting the high costs associated with biotech R&D activities. Despite negative free cash flow, the company has managed to increase cash reserves significantly through financing activities, improving liquidity. The cash flow to net income ratios indicate reliance on financing rather than operational cash generation.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Vicore Pharma Holding AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VICO, the sentiment is Positive. The current price of 8.66 is above the 20-day moving average (MA) of 7.96, above the 50-day MA of 8.20, and above the 200-day MA of 8.05, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 65.02 is Neutral, neither overbought nor oversold. The STOCH value of 77.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VICO.

Vicore Pharma Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	69 Neutral	kr1.21B	4.39	152.78%	―	1533.99%	―
BINV	57 Neutral	kr2.64B	―	-45.80%	―	-0.57%	-39.92%
Sector *	52 Neutral	kr5.61B	10.39	-63.86%	1.96%	27.11%	26.73%
HNSA	49 Neutral	kr2.31B	―		―	20.12%	40.54%
SYNACT	48 Neutral	kr1.09B	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	kr1.92B	―	-42.24%	―	―	-19.44%
VICO	45 Neutral	kr2.01B	―	-40.15%	―	―	63.85%